A late-breaking pooled-analyses from the DELIVER and DAPA-HF trials assessed the efficacy of FARXIGA® (dapagliflozin) in patients with heart failure and deteriorating kidney function, demonstrating clinical benefit. The findings were presented at the European Society of Cardiology Congress 2023.
In this exclusive interview, DocWire News spoke with the presenting investigator Dr. Scott Solomon (Brigham and Women's Hospital, Harvard Medical School) about the findings, which further reinforce the connection between heart failure and kidney disease, and the benefit of treatment with dapagliflozin. #ESCCongress #esc2023